Golden
Celularity

Celularity

Celuarity is a commercial stage cellular therapeutic company focusing on allogenic cellular therapies.

All edits

Edits on 31 Jan 2020
Dawson Sewell"Approved suggestion #717379"
Dawson Sewell edited on 31 Jan 2020 6:18 pm
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Edits on 20 Dec 2019
Golden AI
Golden AI edited on 20 Dec 2019 4:03 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 11 Sep 2019
Golden AI
Golden AI edited on 11 Sep 2019 10:24 am
Edits made to:
Infobox (+1 properties)
Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:53 am
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Edits on 19 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar 2019 10:48 pm
Edits made to:
Article (+7/-7 characters)

Article

On February 15, 2018 Celularity completed their second round of venture funding with $250 million in capital from Colgene (lead investor), United Therapeutics, Sorrento Therapeutics, Section 32, Human Longetivity, CelgeneCelgene, Bill Maris, and Tony Robbins. 

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar 2019 10:45 pm
Edits made to:
Article (+21/-21 characters)

Article

On February 15, 2018 Celularity completed their second round of venture funding with $250 million in capital from Colgene (lead investor), United Therapeutics, Sorrento TherapeuticsSorrento Therapeutics, Section 32, Human Longetivity, Celgene, Bill Maris, and Tony Robbins. 

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 19 Mar 2019 6:24 pm
Edits made to:
Article (+10/-10 characters)

Article

On February 15, 2018 Celularity completed their second round of venture funding with $250 million in capital from Colgene (lead investor), United Therapeutics, Sorrento Therapeutics, Section 32, Human Longetivity, Celgene, Bill MarisBill Maris, and Tony Robbins. 

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 19 Mar 2019 6:11 pm
Edits made to:
Article (+19/-19 characters)

Article

On February 15, 2018 Celularity completed their second round of venture funding with $250 million in capital from Colgene (lead investor), United TherapeuticsUnited Therapeutics, Sorrento Therapeutics, Section 32, Human Longetivity, Celgene, Bill Maris, and Tony Robbins. 

Edits on 15 Mar 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 15 Mar 2019 7:52 pm
Edits made to:
Article (+12/-12 characters)

Article

On February 15, 2018 Celularity completed their second round of venture funding with $250 million in capital from Colgene (lead investor), United Therapeutics, Sorrento Therapeutics, Section 32, Human Longetivity, Celgene, Bill Maris, and Tony RobbinsTony Robbins. 

Edits on 14 Mar 2019
Dawson Sewell
Dawson Sewell edited on 14 Mar 2019 3:14 pm
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Edits on 12 Mar 2019
Dawson Sewell
Dawson Sewell edited on 12 Mar 2019 7:32 pm
Edits made to:
Categories (+1 topics)
Dawson Sewell
Dawson Sewell edited on 12 Mar 2019 7:06 pm
Edits made to:
Infobox (+1 properties)

Infobox

Dawson Sewell
Dawson Sewell edited on 12 Mar 2019 6:22 pm
Edits made to:
Infobox (+9 properties)
Timeline (+3 events) (+602 characters)
Description (+103 characters)
Article (+691 characters)
Further reading (+1 rows) (+4 cells) (+344 characters)
Categories (+1 topics)
Related Topics (+1 topics)
Topic thumbnail

Celularity

Celuarity is a commercial stage cellular therapeutic company focusing on allogenic cellular therapies.

Article

Celuarity is a commercial stage cellular therapeutic company focusing on allogenic cellular therapies. Celularity is headquartered in Warren, New Jersey and was founded in 2016 by Carlos Ramirez, Jerome Zeldis, Jodi Gurney, John R Haines, Robert Hariri, and Steven French.

Funding

Venture round 1

On September 28, 2017 Celularity announced closing a venture round raising $40 million in capital from undisclosed investors. 

Venture round 2

On February 15, 2018 Celularity completed their second round of venture funding with $250 million in capital from Colgene (lead investor), United Therapeutics, Sorrento Therapeutics, Section 32, Human Longetivity, Celgene, Bill Maris, and Tony Robbins. 

Further reading

Title
Author
Link
Type

Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration

Celularity

Web

Infobox

Categories

Related Topics

Timeline

February 15, 2018

Venture round 2

On February 15, 2018 Celularity completed their second round of venture funding with $250 million in capital from Colgene (lead investor), United Therapeutics, Sorrento Therapeutics, Section 32, Human Longetivity, Celgene, Bill Maris, and Tony Robbins. 

September 28, 2017

Venture round 1

On September 28, 2017 Celularity announced closing a venture round raising $40 million in capital from undisclosed investors. 

2016

Founding of Celularity

Celularity is headquartered in Warren, New Jersey and was founded in 2016 by Carlos Ramirez, Jerome Zeldis, Jodi Gurney, John R Haines, Robert Hariri, and Steven French.

Edits on 7 Mar 2019
Golden AI
Golden AI edited on 7 Mar 2019 10:05 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 5 Mar 2019
Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 5 Mar 2019 12:14 pm
Edits made to:
Infobox (+2 properties)
Edits on 13 Feb 2019
Meredith Hanel"Initial topic creation"
Meredith Hanel created this topic on 13 Feb 2019 1:24 am
Edits made to:
Topic thumbnail

 Celularity

Celuarity is a commercial stage cellular therapeutic company focusing on allogenic cellular therapies.

No more activity to show.